Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response

• Published in: Journal of neuro-oncology 2024-04, Vol.167 (2), p.233-241
• Main Authors: Bobholz, Samuel A., Hoefs, Alisha, Hamburger, Jordyn, Lowman, Allison K., Winiarz, Aleksandra, Duenweg, Savannah R., Kyereme, Fitzgerald, Connelly, Jennifer, Coss, Dylan, Krucoff, Max, Banerjee, Anjishnu, LaViolette, Peter S.
• Format: Article
• Language: English
• Subjects: Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Astrocytoma; Autopsy; Bevacizumab; Bevacizumab - therapeutic use; Brain Neoplasms - drug therapy; Brain Neoplasms - genetics; Brain tumors; Glioblastoma; Glioblastoma - drug therapy; Glioblastoma - genetics; Glioma; Humans; Magnetic Resonance Imaging - methods; Medicine; Medicine & Public Health; Metastases; Neoplasm Recurrence, Local - pathology; Neurology; Oncology; Phenotypes; Phenotyping; Survival
• ISSN: 0167-594X; 1573-7373; 1573-7373
• DOI: 10.1007/s11060-024-04593-7

Background Autopsy-based radio-pathomic maps of glioma pathology have shown substantial promise inidentifying areas of non-enhancing tumor presence, which may be able to differentiate subsets of patients that respond favorably to treatments such as bevacizumab that have shown mixed efficacy evidence. We tested the hypthesis that phenotypes of non-enhancing tumor fronts can distinguish between glioblastoma patients that will respond favorably to bevacizumab and will visually capture treatment response. Methods T1, T1C, FLAIR, and ADC images were used to generate radio-pathomic maps of tumor characteristics for 79 pre-treatment patients with a primary GBM or high-grade IDH1-mutant astrocytoma for this study. Novel phenotyping (hypercellular, hypocellular, hybrid, or well-circumscribed front) of the non-enhancing tumor front was performed on each case. Kaplan Meier analyses were then used to assess differences in survival and bevacizumab efficacy between phenotypes. Phenotype compartment segmentations generated longitudinally for a subset of 26 patients over the course of bevacizumab treatment, where a mixed effect model was used to detect longitudinal changes. Results Well-Circumscribed patients showed significant/trending increases in survival compared to Hypercellular Front (HR = 2.0, p  = 0.05), Hypocellular Front (HR = 2.02, p  = 0.03), and Hybrid Front tumors (HR = 1.75, p  = 0.09). Only patients with hypocellular or hybrid fronts showed significant survival benefits from bevacizumab treatment (HR = 2.35, p  = 0.02; and HR = 2.45, p  = 0.03, respectively). Hypocellular volumes decreased by an average 50.52 mm 3 per day of bevacizumab treatment ( p  = 0.002). Conclusion Patients with a hypocellular tumor front identified by radio-pathomic maps showed improved treatment efficacy when treated with bevacizumab, and reducing hypocellular volumes over the course of treatment may indicate treatment response.